Movement Alert｜Gilead Sciences Rises 3.02% in Regular Trading, Lifted by Broad Biotech Sector Strength

Market Focus07-17 03:00

On July 17, Gilead Sciences rose 3.02% in regular trading, trading at $135.685 per share, with turnover of $4.68 billion, tracking broad-based gains across the biotechnology sector.

The move was driven by sector-wide strength among large-cap biotech names, with Gilead's gain largely in lockstep with industry peers. Within the Biotechnology sector, AbbVie rose 3.0%, Amgen gained 2.89%, and Vertex Pharmaceuticals advanced 1.32%, reflecting a coordinated sector rally rather than a company-specific catalyst.

On the fundamental front, Gilead recently secured FDA approval for Trodelvy as a first-line treatment for advanced triple-negative breast cancer, both as monotherapy and in combination with Merck's Keytruda. The NCCN has listed it as a Category 1 preferred first-line option regardless of PD-L1 status. Additionally, HSBC recently upgraded the stock to Buy with a target price of $155, providing valuation support following a prior pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178122586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178122586","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Gilead Sciences Rises 3.02% in Regular Trading, Lifted by Broad Biotech Sector Strength","media":"Market Focus","content":"<p><p>On July 17, Gilead Sciences rose 3.02% in regular trading, trading at $135.685 per share, with turnover of $4.68 billion, tracking broad-based gains across the biotechnology sector.</p><p>The move was driven by sector-wide strength among large-cap biotech names, with Gilead's gain largely in lockstep with industry peers. Within the Biotechnology sector, AbbVie rose 3.0%, Amgen gained 2.89%, and Vertex Pharmaceuticals advanced 1.32%, reflecting a coordinated sector rally rather than a company-specific catalyst.</p><p>On the fundamental front, Gilead recently secured FDA approval for Trodelvy as a first-line treatment for advanced triple-negative breast cancer, both as monotherapy and in combination with Merck's Keytruda. The NCCN has listed it as a Category 1 preferred first-line option regardless of PD-L1 status. Additionally, HSBC recently upgraded the stock to Buy with a target price of $155, providing valuation support following a prior pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Gilead Sciences Rises 3.02% in Regular Trading, Lifted by Broad Biotech Sector Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Gilead Sciences Rises 3.02% in Regular Trading, Lifted by Broad Biotech Sector Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 03:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 17, Gilead Sciences rose 3.02% in regular trading, trading at $135.685 per share, with turnover of $4.68 billion, tracking broad-based gains across the biotechnology sector.</p><p>The move was driven by sector-wide strength among large-cap biotech names, with Gilead's gain largely in lockstep with industry peers. Within the Biotechnology sector, AbbVie rose 3.0%, Amgen gained 2.89%, and Vertex Pharmaceuticals advanced 1.32%, reflecting a coordinated sector rally rather than a company-specific catalyst.</p><p>On the fundamental front, Gilead recently secured FDA approval for Trodelvy as a first-line treatment for advanced triple-negative breast cancer, both as monotherapy and in combination with Merck's Keytruda. The NCCN has listed it as a Category 1 preferred first-line option regardless of PD-L1 status. Additionally, HSBC recently upgraded the stock to Buy with a target price of $155, providing valuation support following a prior pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"","article_id":"1178122586","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178122586","pubTimestamp":1784228445,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 17, Gilead Sciences rose 3.02% in regular trading, trading at $135.685 per share, with turnover of $4.68 billion, tracking broad-based gains across the biotechnology sector.The move was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"走势警报|受生物技术板块普遍走强提振，吉利德科学在常规交易中上涨 3.02%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"On July 17, Gilead Sciences rose 3.02% in regular trading, trading at $135.685 per share, with turnover of $4.68 billion, tracking broad-based gains across the biotechnology sector.The move was driven by sector-wide strength among large-cap biotech names, with Gilead's gain largely in lockstep with industry peers. Within the Biotechnology sector, AbbVie rose 3.0%, Amgen gained 2.89%, and Vertex Pharmaceuticals advanced 1.32%, reflecting a coordinated sector rally rather than a company-specific catalyst.On the fundamental front, Gilead recently secured FDA approval for Trodelvy as a first-line treatment for advanced triple-negative breast cancer, both as monotherapy and in combination with Merck's Keytruda. The NCCN has listed it as a Category 1 preferred first-line option regardless of PD-L1 status. Additionally, HSBC recently upgraded the stock to Buy with a target price of $155, providing valuation support following a prior pullback.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178122586","isCrawlerRequest":true}